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A B S T R A C T
There are a number of approaches to studying medication-taking behavior. Self-report measures have the benefits of
being cheap, easy to administer, non-intrusive, and able to provide information on attitudes and beliefs about medication.
Potential limitations to self-report are that the ability to understand the items, and willingness to disclose information,
can affect response accuracy and, thus, questionnaire validity. A computerized systematic search of the PubMed databases
identified articles on scales for medication adherence measuring using the MeSH terms medication adherence, compli-
ance, and persistence combined with the terms questionnaire self-report. Adherence scales have identified mostly in the
last few years (2005–2012). One of the main sources has been article (Lavsa et. al) which evaluated literature describing
medication adherence surveys/scales to gauge patient behaviors at the point of care. Articles were included if they evalu-
ated or reviewed self-reported adherence medication scale applicable to chronic diseases and with a good coefficient of in-
ternal consistency reliability (Cronbach’s a (alpha)). Articles that contained data about self-report medication adherence
scales use were included. A total of about one hundred articles were identified. Of those articles, 20% (20 of 100) were in-
cluded in the review because of their relevance to the article topic. This article describes various self-report scales by
which to monitor medication adherence, their advantages and disadvantages, and discusses the effectiveness of their ap-
plication at different chronic diseases. There are many self-report scales for measuring medication adherence and their
derivatives (or subscales). Due to the different nature of the diseases, there is no gold-standard scale for measuring medi-
cation adherence. It can be nevertheless concluded that the nearest to gold-standard is the Medication Adherence Ques-
tionnaire (MAQ) scale by Morisky et.al. but we found better internal consistency reliability in some other scales.
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Introduction
Medication nonadherence is a growing concern to
healthcare systems, physicians and other stakeholders
because of mounting evidence that it is prevalent and as-
sociated with adverse outcomes and higher costs of care.
Patients with chronic diseases often receiving multiple
medications, are at higher risk for nonadherence to med-
ication and medication adherence can be essential for im-
proving health outcomes. To date, measurement of pa-
tient medication adherence and use of interventions to
improve adherence is rare in clinical and pharmaceutical
practice. Physicians’ lack of knowledge and patients’ lack
of awareness account for about 70% of non-adherence,
indicating the necessity to improve physician education,
and patient involvement1.
There are a number of approaches to studying medi-
cation-taking behavior. The most precise methods are di-
rectly observed therapy, biological methods and measure-
ment of the level of medicine or metabolite (such as blood
or urine drug concentrations)2. Numerous other meth-
ods include clinician reports, pill counts, rates of pre-
scription refills, electronic medication monitors, patient
diaries, and patient self-report measures that have the
benefits of being cheap, brief, acceptable to patients,
valid, reliable, have the ability to distinguish between
different types of non-adherence, easy to administer,
non-intrusive, and able to provide information on atti-
tudes and beliefs about medication.
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Potential limitations to self-report are that ability to
understand the items, and willingness to disclose infor-
mation, can affect response accuracy and thus question-
naire validity.
In the study the most common self-report question-
naires for measuring medication adherence were de-
scribed, what is the basis for interventions to improve
medication adherence.
Among the already well-known scales, the new one is
inaugurated in Croatia: Culig adherence scale, applied in
some investigations in Zagreb, Croatia.
The aim was to evaluate literature describing medica-
tion adherence surveys/scales to gauge patient behaviors
at the point of care.
Materials and Methods
A computerized systematic search of the PubMed da-
tabases identified articles on self-report scales for medica-
tion adherence measuring using the MeSH terms: medi-
cation adherence, compliance, and persistence combined
with the terms questionnaire self-report. Self-report ad-
herence scales are identified mostly in the last few years
(2005–2012). One of the main sources was an article3
which evaluated literature describing medication adher-
ence surveys/scales to gauge patient behaviors at the
point of care.
Articles were included if they evaluated or reviewed
self-reported adherence medication scale applicable at
chronic diseases and with good coefficient of internal
consistency reliability (Cronbach’s a (alpha)).
A total of about one hundred articles was identified.
Of the articles, 20% (20 of 100) were included in the com-
mentary because of their relevance to the article topic.
This article describes various self-report scales by which
to monitor medication adherence, their advantages and
disadvantages, and discusses the effectiveness of their
application at different chronic diseases.
Results
1. Medication Adherence Questionnaire (MAQ)
The best known and most widely used scales for re-
search adherence is the Medication Adherence Question-
naire (MAQ) by Morisky et al.4 (Figure 1), which has several
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Fig. 1. MAQ (Medication Adherence Questionnaire)
advantages: identifies barriers to nonadherence, it is the
shortest, easiest to score and very adaptable for various
groups of medication. MAQ identifies barriers to nonad-
herence but not self-efficacy. Adherence to the medical
regimen continues to rank as a major clinical problem in
the management of patients with essential hypertension,
as in other conditions treated with drugs and lifestyle
modification. This article reviews the psychometric prop-
erties and tests the concurrent and predictive validity of
a structured four-item self-reported adherence measure
(alpha reliability=0.61), which can be easily integrated
into the medical visit. Items in the scale address barriers
to medication-taking and permit the health care provider
to reinforce positive adherence behaviors. Another study
assessed the factor structure and validity of the MAQ
with cigarette smokers5. A principal component analysis
was conducted on MAQ scores from a sample of smokers
present for treatment in a clinical trial of naltrexone and
the nicotine patch for smoking cessation. The purposeful
nonadherence factor of the MAQ may be used as a brief
screening tool for medication adherence with cigarette
smokers seeking treatment. Information obtained with
this questionnaire could be used to counsel patients re-
garding the importance of medication adherence.
The usefulness of the Patient Medication Adherence
Questionnaire (PMAQ) was evaluated in HIV-infected
patients on protease inhibitor (PI)-containing regimens6.
Adherence to antiretroviral medications is critically im-
portant for the success of therapy in patients treated for
HIV infection. Patients’ psychological and behavioral
factors are central in the acceptance and adherence to
antiretroviral therapy. To improve the feasibility and the
reproducibility of the PMAQ, the authors propose a re-
vised form of the PMAQ, focusing on the variables identi-
fied as strong predictors of adherence.
2. Self-efficacy for Appropriate Medication Use
(SEAMS)
The Self-efficacy for Appropriate Medication Use
(SEAMS) was developed by a multidisciplinary team
with expertise in medication adherence and health liter-
acy. Its psychometric properties were evaluated among
436 patients with coronary heart disease and other comor-
bid conditions7. Reliability was evaluated by measuring
internal consistency and test-retest reliability. The final
13-item scale had good internal consistency reliability
(Cronbach’s alpha=0.89). The SEAMS is a reliable and
valid instrument that may provide a valuable assessment
of medication self-efficacy in chronic disease manage-
ment, and appears appropriate for use in patients with
low literacy skills.
Because of poor adherence to oral osteoporosis medi-
cations, SEAMS was applied on five hundred women
aged 55 years and older who were newly prescribed daily
or weekly oral bisphosphonates, were randomly selected
from Kaiser Permanente Southern California, a large in-
tegrated health care delivery system, and mailed a self-
-administered survey that included, among others, and
SEAMS8. Internal consistency reliability was evaluated
using Cronbach’s alpha (0.82).
3. Brief Medication Questionnaire (BMQ)
Brief Medication Questionnaire (BMQ) is a self-report
tool for screening adherence and barriers to adherence.
It has three main question headings and multiple sub-
questions (Figure 2)9,10. The tool includes:
¿ a 5-item Regimen Screen that asks the patients about
their medications that they were currently taking.
Questions are asked to list the name of each medi-
cation, frequency of medication per day, number of
days and times they have received each medication
along with the number of times the patient missed
taking medications in the past week,
¿ a 2-item Belief Screen consists of two questions that
ask the patients whether they had any difficulty
with any of the medications, and does the medica-
tion bother them in any way,
¿ a 2-item Recall Screen assesses the patient’s diffi-
culty in recalling and remembering the dosage regi-
men of their medications, and
¿ a 2-item Access screen that evaluates the patient
difficulty in buying and refilling their medications
in time.
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Fig. 2. Brief Medication Questionnaire (BMQ)
This method was applied in the cross-sectional study
of hypertensive people enrolled at least six months in the
program to assist hypertensive and diabetic individuals,
provided in Brazil11.
The analysis of BMQ in this study showed that the
regimen screen performed better than the other screens
and the Medication Adherence Questionnaire (MAQ) for
the identification of low adherence among people with
uncontrolled hypertension. This finding is similar to the
original study performed in the USA, which used a more
reliable gold standard medication event monitoring sys-
tems (MEMS) than the insufficient acquisition of medi-
cations and uncontrolled blood pressure, although it was
obtained in a smaller sample of patients (43 vs. 206).
On the BMQ regimen screen, the authors found 48.1%
of patients with low adherence. The clinical profile of
these patients (higher blood pressure, greater prevalence
of CRI and worse self-perceived health) is insufficient to
identify low adherence; therefore a more objective meth-
od to evaluate adherence is needed, potentially using the
BMQ regimen screen which was strongly associated with
control of blood pressure. From the point of view of pro-
gram planning in public health, such evaluation can indi-
cate which patients should receive educational reinforce-
ment, pharmaceutical support and multidisciplinary care
and which require adjustment of therapeutic regimens.
Evaluation of adherence may help clinicians discrimi-
nate between inadequate use of medication and insuffi-
cient treatment regimen.
4. The Hill-Bone Compliance Scale
The Hill-Bone Compliance Scale addresses barriers
and self-efficacy but are limited in their generalizability.
The Hill-Bone Compliance Scale focuses on hypertensive
patients. This scale assesses patient behaviors for three
important behavioral domains of high blood pressure
treatment: 1) reduced sodium intake; 2) appointment
keeping; and 3) medication taking. This scale is com-
prised of 14 items in three subscales. Each item is a four
point Likert type scale (Table 1). The content validity of
the scale was assessed by a relevant literature review and
an expert panel, which focused on cultural sensitivity
and appropriateness of the instrument for low literacy12.
This scale was validated in most investigations, among
others for use in a South African primary health care
setting13, because hypertension is prevalent, under-diag-
nosed, and inadequately treated in Black South Africans.
The authors demonstrated criterion validity and internal
consistency for a modified Hill-Bone. Results compare fa-
vorably with those from an urban African-American set-
ting (standardized Cronbach alpha was 0.74–0.84). This
study demonstrates that many of the behavioral aspects
of the fundamental elements of high blood pressure care
and control, such as the medication taking, appointment
keeping, and salt intake reduction, are measurable across
cultures. Second, the study showed that vigorous psycho-
metric methods can be used effectively in different cul-
tural groups. Third, the study demonstrates that both
concurrent and predictive validity can be assessed quick-
ly in a clinical setting. In cases of insufficiently controlled
blood pressure, it is important for practitioners to distin-
guish between »nonadherence« and »nonresponse« to anti-
hypertensive drug treatment14. A reliable and valid ad-
herence measurement based on the patient’s self-report
may be helpful in daily practice. In a primary care sample
with 353 hypertensive patients, the authors applied two
self-rating instruments to assess medication adherence
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1. How often do you forget to take your HBP medicine? 1 2 3 4 8 9
2. How often do you decide not to take your HBP medicine? 1 2 3 4 8 9
3. How often do you eat salty food? 1 2 3 4 8 9
4. How often do you shake salt, fondor, or aromat on your food before you eat it? 1 2 3 4 8 9
5. How often do you eat fast food? (KFC, McDonalds, fat cook, fish and chips) 1 2 3 4 8 9
6. How often do you get the next appointment before you leave the clinic? 1 2 3 4 8 9
7. How often do you miss scheduled appointments? 1 2 3 4 8 9
8. How often do you leave the dispensary without obtaining your prescribed pills?
(due to long line, closure of the clinic, forgot)
1 2 3 4 8 9
9. How often do you run out of HBP pills? 1 2 3 4 8 9
10. How often do you skip your HBP medicine 1–3 days before you go to the clinic? 1 2 3 4 8 9
11. How often do you miss taking your HBP pills when you feel better? 1 2 3 4 8 9
12. How often do you miss taking your HBP pills when you feel sick? 1 2 3 4 8 9
13. How often do you take someone else’s HBP pills? 1 2 3 4 8 9
14. How often do you miss taking your HBP pills when you care less? 1 2 3 4 8 9
(the »Hill-Bone Compliance to High Blood Pressure The-
rapy Scale« and Morisky’s »Self-Reported Measure of
Medication Adherence«) and comparing their psychome-
tric properties. The use of both scales cannot be recom-
mended. They showed considerable floor effects, and
their ability to identify medication adherence was incon-
sistent for nearly every third patient. The power of both
scales to predict uncontrolled blood pressure was essen-
tially a chance. The underlying conceptual framework of
medication adherence therefore needs to be rethought.
Turkish version of the Hill-Bone Compliance Scale to
high blood pressure therapy scale was used to assess the
validity and reliability for use in primary care in Tur-
key15. The Turkish Hill-Bone scale presented a factor
structure consistent with the original scale, had a high
level of internal consistency. It can be used for assessing
hypertension patients’ compliance with Turkish primary
care settings.
Another objective of the study was to determine the
reliability of the Hill-Bone Compliance Scale among el-
derly hypertensive patients16. Reliable approaches for
measuring antihypertensive medication compliance in
the outpatient setting are not readily available. The au-
thors conducted a cross-sectional survey of community-
-dwelling patients attending the hypertension section of
the Internal Medicine Clinic in a large multispecialty
group practice. Participants (N=239) completed a self-
-administered questionnaire consisting of demographic
questions and the Hill-Bone Compliance to High Blood
Pressure Therapy Scale, which includes a nine-item me-
dication compliance subscale. The medication compli-
ance subscale of the Hill-Bone Compliance Scale appears
reliable and may be a useful tool for detecting noncom-
pliant patients in outpatient settings.
5. The Medication Adherence Rating Scale
(MARS)
Adherence to medication is an important predictor of
illness course and outcome in psychosis. The Medication
Adherence Rating Scale (MARS) was developed from Mo-
risky et al’s Medication Adherence Questionnaire (MAQ),
is a ten-item self-report measure of medication adher-
ence in psychosis (Table 2)17. To summarize, the MARS is
a quick, non-intrusive measure of medication adherence.
Its reliability is adequate, but validity appears only mod-
erate-weak. Items in the MARS about attitude to medica-
tion may be informative to clinicians identifying barriers
to adherence in individual cases, but do not appear to be
valuable in predicting adherence behavior over a large
sample. Factor 1 (medication adherence behavior), corre-
sponding to the Medication Adherence Questionnaire
(MAQ), may be superior for this purpose. The MARS to-
tal score reproduced the expected relationships of higher
adherence with more insight into the need for medica-
tion, and higher adherence with less psychopathology.
The internal consistency of the MARS was moderate
(alpha=0.60), but lower than the value produced by
Thompson et al.18 during the original development of the
scale (alpha=0.75). This may not represent a weakness
of the scale, however, as there are reasons to expect a re-
duced alpha value for scales with the format of the
MARS, notably the binary response choice, a small num-
ber of items, and scale multidimensionality. Though it is
likely that the internal consistency of the MARS could be
improved either by adding more response options or by
adding more items, it is debatable whether this would
constitute an improvement to the measure, or whether it
would compromise its quick, simple format.
In addition to replicating the three factors of the
MARS, the current study examined the relationships of
the individual factor scores. Factor 1 (adherence behav-
ior) was the only factor total score to correlate with
keyworker-rated medication adherence. This factor cor-
relation was of equal strength to the whole scale correla-
tion. It therefore appears that where the concern is sim-
ply whether or not someone is taking their medication,
factor 1 may be a better indicator than the whole MARS
scale. This four item subscale is quicker to administer,
has a higher internal consistency than the overall scale,
and appears valid for this purpose. Factor 2 total score
(attitude towards medication) correlated with insight
into illness and insight into the effects of medication but
failed to correlate with keyworker rated adherence. The
current study16 has a number of limitations. A single
item keyworker rating for medication adherence was
used to determine the concurrent validity of the MARS.
Although the proportions of participants rated as being
adherent (69%) or not adherent (31%) to their medica-
tion regimen using this method was in line with previous
estimates19,20,21 a multi-item measure would have been
preferable. The sample was mixed, containing both inpa-
tients and outpatients, and it is possible that the inaccu-
racy was introduced due to retrospective completion
among inpatients. The results do not identify an effect of
the inpatient completion of the measure, but placing this
extra memory demand on questionnaire completion, es-
pecially among a group who may have cognitive deficits,
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TABLE 2
FREQUENCIES OF RESPONSES ON THE MARS
Nr Claim or question Compliant
1 Do you ever forget to take your medication? No
2 Are you careless at times at taking medication? No
3 When you feel better do you sometimes stop
taking your medication?
No
4 Sometimes if you feel worse when you take the
medication do you stop taking it?
No
5 I take my medication only when I am sick No
6 It is unnatural for my mind and body to be
controlled by medication
No
7 My thoughts are clearer on medication Yes
8 By staying on medication, I can prevent getting
sick
Yes
9 I feel weird, like a zombie, on medication No
10 The medication makes me feel tired and sluggish No
Compliant='No' response for q1–6, 9–10 'Yes' response for q7,8.
was not ideal. An all-outpatient sample would have been
preferable to eliminate this problem. Furthermore, all
participants had consented to a treatment trial, so may
not be fully representative of those with psychosis. In
particular, they are likely to be a better engaged group.
6. Adherence to Refills and Medications Scale
(ARMS)
The Adherence to Refills and Medications scale (ARMS)
was developed, pilot tested, and administered to 435 pa-
tients with coronary heart disease in an inner-city pri-
mary care clinic22. Psychometric evaluation performed
overall and by literacy level, included an assessment of
internal consistency, test-retest reliability, and factor anal-
ysis. Criterion-related validity was evaluated by compar-
ing scores with Morisky’s self-reported measure of ad-
herence, medication refill adherence, and blood pressure
measurements. Lexile analysis was performed to assess
the reading difficulty of the instrument.
The final 12-item scale had high internal consistency
overall (Cronbach’s alpha=0.814) and among patients
with inadequate (alpha=0.792) or marginal/adequate lit-
eracy skills (alpha=0.828) (Table 3). Factor analysis yiel-
ded two subscales, which pertained to taking medica-
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TABLE 3
ADHERENCE TO REFILLS AND MEDICATION SCALE
1. How often do you miss scheduled appointments?
2. How often do you forget to take your medicine?
3. How often do you decide not to take your medicine?
4. How often do you forget to get prescriptions filled?
5. How often do you run out of medicine?
6. How often do you skip a dose of your medicine before you go to the doctor?
7. How often do you miss taking your medicine when you feel better?
8. How often do you miss taking your medicine when you feel sick?
9. How often do you take someone else’s medicine?
10. How often do you miss taking your medicine when you are careless?
11. How often do you change the dose of your medicines to suit your needs (like when you take a more or less pill than you’re
supposed to)?
12. How often do you forget to take your medicine when you are supposed to take it more than once a day?
13. How often do you put off refilling your medicines because they cost too much money?
14. How often do you plan ahead and refill your medicines before they run out?
TABLE 4
ADHERENCE SCALE CULIG
Cause of nonadherence Never
Very rare Sometimes Often
(1–2 yearly) (3–5 yearly) (more than 5 yearly)
1 I was not at home 0 1 2 3
2 The drug was not available due to short supply 0 1 2 3
3 I just forgot 0 1 2 3
4 I take a number of drugs several times a day 0 1 2 3
5 I wanted to avoid side effects 0 1 2 3
6 I did not want other people seeing me taking drug 0 1 2 3
7 My doctor frequently changes my therapy 0 1 2 3
8 I felt the drug to be toxic/harmful 0 1 2 3
9 I was sleepy at medication time 0 1 2 3
10 I had cold 0 1 2 3
11 I felt depressed or broken 0 1 2 3
12 I had problems with medication timing 0 1 2 3
13 I consumed all of it 0 1 2 3
14 I felt well 0 1 2 3
15 I was afraid of developing drug dependence 0 1 2 3
16 The drug was too expensive 0 1 2 3
tions as prescribed and refilling medications on schedule.
The ARMS correlated significantly with the Morisky ad-
herence scale (Spearman’s rho=–0.651, p<0.01), and it
correlated more strongly with measures of refill adher-
ence than did the Morisky scale. Patients with low ARMS
scores (which indicated better adherence) were signifi-
cantly more likely to have controlled diastolic blood pres-
sure (p<0.05), and tended to have better systolic blood
pressure control. Lexile analysis demonstrated that the
instrument had a favorable reading difficulty level below
the eight grades. The ARMS is a valid and reliable medi-
cation adherence scale when used in a chronic disease
population, with good performance characteristics even
among low-literacy patients.
7. Scale for measurement adherence to medication
applied in Zagreb, Croatia
This scale was applied in the study that was designed
as a cross-sectional survey by use of a self-administered
33-item questionnaire23. The questionnaire listed 16 com-
mon reasons for nonadherence and study subjects had to
answer questions on each of these reasons as the possible
cause of his/her nonadherence (Table 4). This final 16-
-item scale had good internal consistency reliability (Cron-
bach’s alpha=0.89)24. These answers were used to ana-
lyze the impact of each of these reasons for nonadherence.
The study included 635 individuals collecting or buy-
ing drugs for the treatment of chronic diseases, with spe-
cial reference to subjects taking antihypertensive agents
(N=361). The survey was conducted at Zagreb (Croatia)
pharmacies and the questionnaire was filled out by study
subjects with instructions and help provided by the phar-
macist as questionnaire administrator.
According to medication adherence, study subjects
were divided into two groups of adherent and nonadhe-
rent subjects, as declared by themselves. The subjects an-
swering the respective question that they had never
failed to take their medication on time were considered
as adherent, and all others as nonadherent subjects.
In Table 5 are the references of scales for measuring
adherence, in Table 6 scales are systematized according
to disease suitable for measuring adherence at certain
diseases and in Table 7 are Cronbach a, coefficient com-
monly used as a measure of the internal consistency reli-
ability of an adherence measurement scale. The mostly
scales have good internal consistency reliability, because
some professionals as a rule of thumb require a reliabil-
ity of 0.70 or higher25.
J. ^ulig and M. Leppée: Scales for Measuring Adherence, Coll. Antropol. 38 (2014) 1: 55–62
61
TABLE 5








Toll BA, McKee SA 4

















6. ARMS Kripalani 21
7. Culig Culig 22
TABLE 6
SCALES SUITABLE FOR MEASURING ADHERENCE
AT CERTAIN DISEASES
No Scale 1 2 3 4 5 6 7 8
1. Morisky-Green + + +
2. SEAMS + + +




7. Culig + +
1 – Chronic disease, 2 – Arterial hypertension, 3 – Coronary heart
disease, 4 – Diabetes, 5 – Psychosis, 6 – AIDS/HIV, 7 – Osteopo-
rosis, 8 – Smoking cessation
TABLE 7
CRONBACH a AT SOME ARTICLES REGARDING TO
ADHERENCE MEASURING
No Scale Literature Cronbach a
1. Morisky-Green
Morisky-Green 0.61
Toll BA, McKee SA –

















6. ARMS Kripalani 0.81
7. Culig Culig 0.89
Conclusions
There are many self-report scales for measuring med-
ication adherence and their derivatives (or subscales).
Due to the different nature of the diseases, there is no
gold-standard scale for measuring medication adherence.
It can be nevertheless concluded that the most fre-
quently used is a Medication Adherence Questionnaire
(MAQ) scale by Morisky et al.4, but we found a better in-
ternal consistency reliability in some other scales.
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OD MORISKY DO HILL-BONE; RAZLI^ITE SKALE ZA MJERENJE USTRAJNOSATI
PREMA TERAPIJI
S A @ E T A K
Postoji niz na~ina kojima se utvr|uje ustrajnost pacijenata prema terapiji. Naro~ito su pogodna ispitivanja koja se
svode na iskazivanje samih pacijenata s obzirom da su jeftina i neposredna, a ujedno dolazimo do stavova pacijenata o
uzimanju lijekova. Ograni~enja takvih istra`ivanja su mogu}a nedovoljna razumljivost pitanja od strane pacijenata te
nepovjerenje i strah pacijenata vezanih uz objavljivanja podataka o uzimanju lijekova. Pretra`ivanjem PubMeda uz
klju~ne rije~i adherence, compliance i persistence (ustrajnost) te self-report questionnaire do{lo se do svih do sada
poznatih skala za mjerenje ustrajnosti. Ve}ina skala je dizajnirana u zadnjih nekoliko godina (2005–2012). Jedan od
najzna~ajnijih izvora je ~lanak Lavse i dr. u kojem se opisuju i evaluiraju skale za ocjenjivanje ustrajnosti. Kriterij
uklju~enja bio je mogu}nost primjene kod utvr|ivanja ustrajnosti u kroni~nih bolesti i relativno visoki koeficijent unu-
tarnje konzistentnosti (Cronbach a). Pregledano je oko stotinjak ~lanaka i 205 je uklju~eno u ovaj prikaz. U ~lanku se
prikazuju pojedine skale zajedno sa svojim prednostima i nedostacima te se raspravlja o mogu}nostima identifikacije
uzroka neustrajnosti kod pojedinih kroni~nih bolesti. Iako postoji niz razli~itih skala, jo{ uvijek se ne mo`e govoriti o
zlatnom standardu, iako je tome najbli`a medication Adherence Questionnaire (MAQ) skala nazvana jo{ i, prema svom
autoru, Morisky skala.
J. ^ulig and M. Leppée: Scales for Measuring Adherence, Coll. Antropol. 38 (2014) 1: 55–62
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